UK markets closed

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.51-1.83 (-5.32%)
As of 03:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close34.33
Open33.55
Bid32.37 x 200
Ask32.52 x 100
Day's range32.25 - 34.09
52-week range13.57 - 53.08
Volume433,510
Avg. volume748,745
Market cap2.22B
Beta (5Y monthly)1.89
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

    – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for

  • GlobeNewswire

    Arvinas to Present at Upcoming Investor Conferences

    NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside ch

  • GlobeNewswire

    Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

    NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief